| Mepha Pharma AG - Octreotid-Mepha LA 30 mg, Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension |
| 67154 | | 03 | | Octreotid-Mepha LA 30 mg | | Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension | | H01CB02 | | Octreotid | | 19.07.2019 | | |
|
| Composition |
| Praeparatio sicca: octreotidum 30 mg ut octreotidi acetas, poly(lactidum-co-glycolidum), mannitolum, pro vitro.
Solvens: carmellosum natricum corresp. natrium 1.512 mg, mannitolum, poloxamerum 188, aqua ad iniectabile q.s. ad solutionem pro 2 ml. |
| Packungsbestandteile |
| Lyophilisat et solvant | | | | | | | | Principe actif | Concentr. | informations additionels |
|---|
| Octreotide | 30 mg | Praeparatio sicca |
| | BAG: Principe actif | Concentr. |
|---|
| Octreotide | 30 mg |
| | | | Agents auxilliaires |
|---|
| Mannitol | | Poly(Lactidum-Co-Glycolidum) |
| |
| Solvens | | | Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension | | | | | | | | | BAG: Principe actif | Concentr. |
|---|
| Octreotide | 30 mg |
| | | | Agents auxilliaires | Concentr. |
|---|
| Carmellose Sodique | | | Mannitol | | | Poloxamer | 188 |
| |
|
| numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 003 | | | | | | Non |
|
